Aduhelm tied to brain swelling in nearly 40% of patients, but few have symptoms, drugmaker says … Operators push back as nursing homes fined nearly $1 million over state vaccination rules … BP drug...
Early Alzheimer’s diagnosis may unintentionally hamper social engagement
Nov 23, 2021
Clinicians should identify strategies to alleviate the social impacts of dementia diagnoses and encourage patients to mobilize informal support networks, researchers say.
Trial begins of nasal vaccine for Alzheimer disease
Nov 18, 2021
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
Experts: More research needed before treating patients with controversial Alzheimer’s drug Aduhelm
Sep 13, 2021
The majority of patients with Alzheimer’s disease would not have been eligible to take part in the clinical trials of the new controversial Alzheimer’s drug aducanumab (Aduhelm), according...
Having a good listener in one’s life may help slow cognitive decline: study
Aug 18, 2021
Older adults who have regular interactions with active listeners are more likely to have cognitive functioning that contradicts evidence of dementia-related brain changes, a new study finds.
VA will not add Alzheimer’s drug Aduhelm to its formulary
Aug 12, 2021
The Department of Veterans Affairs has chosen not to include aducanumab (Aduhelm) in its national list of covered drugs, citing risk of adverse events and lack of evidence of positive impact on cognition,...
Relapse risk for psychosis in dementia lower with continued pimavanserin
Jul 22, 2021
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
BREAKING: First appropriate use guidance published for Alzheimer’s drug Aduhelm
Jul 27, 2021
The first set of guidelines has been published for clinicians who wish to prescribe the new drug aducanumab (Aduhelm) and to properly monitor its administration. The recommendations fill the gaps between...
Also in the News for Tuesday, July 20
Jul 20, 2021
Providers will end 2021 better than they started: report … Early-onset dementia prevalence higher than previously estimated, with Alzheimer’s diagnoses leading the surge … Rare COVID-19 vaccine breakthroughs...
Slow buy-in: Only 3% of neurologists have written Aduhelm prescriptions so far
Jul 15, 2021
Neurologists are very aware of Biogen’s newly approved Alzheimer’s drug, but few have prescribed it so far, a real-time study of the brand’s market launch has found.